Zai Lab Enters $1.4 Billion Deal with MacroGenics for Four Immunoncology Drugs
publication date: Jun 16, 2021
Shanghai's Zai Lab announced a four-drug immunonocology deal with MacroGenics worth over $1.4 billion. Both companies will contribute IP to the products. Zai Lab will have Asian and/or global rights for up to four CD3- or CD47-based bispecific molecules from Macrogenics, plus Zai will have rights to MacroGenics' DART® and TRIDENT® multi-specific platforms. In return, Zai will provide MacroGenics with rights to specific CD47 IP for select tumor targets. Zai will make an upfront payment of $25 million and an investment of $30 million in MacroGenics, plus up to $1.4 billion in milestone payments. More details....
Stock Symbols: (NSDQ: ZLAB; HK: 9688) (NSDQ: MGNX)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.